Literature DB >> 30933574

When Is The Price Of A Drug Unjust? The Average Lifetime Earnings Standard.

Ezekiel J Emanuel1.   

Abstract

The majority of Americans believe that lowering drug prices should be the top health care priority for the federal government. Yet drug costs as a proportion of the country's medical expenditures have increased substantially in recent years. Because drugs are basic necessities, and because how much society should contribute toward providing basic necessities is a question of justice, policies regarding drug prices must fulfill principles of justice, not just economic efficiency. In this article I define a standard for when the price of a drug is unjust, using a cross-disciplinary ethical approach. Based on four principles, I propose the average lifetime earnings standard for affordability. According to this standard, a drug price is unfair if it exceeds 11 percent of the average American's disposable income. This suggests that current prices for many drugs are excessive and unjust.

Year:  2019        PMID: 30933574     DOI: 10.1377/hlthaff.2018.05052

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Authors:  Paul Sorum; Christopher Stein; Danielle Wales; David Pratt
Journal:  Int J Health Serv       Date:  2022-05-12       Impact factor: 1.851

2.  Multiples of Median Income: A Tool to Call out Drugs that are High Cost and Low Value.

Authors:  Thomas E Kottke; Andrew R Zinkel; Charles J Fazio
Journal:  Perm J       Date:  2019-11-15

3.  Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?

Authors:  Cong Huang; Carolina Oi Lam Ung; Haishaerjiang Wushouer; Lin Bai; Tao Huang; Xinyi Li; Xiaodong Guan; Luwen Shi
Journal:  Health Res Policy Syst       Date:  2022-01-03

4.  Drug costs in context: assessing drug costs in cost-of-illness analyses.

Authors:  T Joseph Mattingly; Shannon Weathers
Journal:  Drugs Context       Date:  2022-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.